Calls for papers
-
Researchers from the University of Liverpool have partnered with nebulizer maker Aerogen on a project called “Treatment of Respiratory Infections with inhaled AntimicrobiaLs” (TRIAL), which will develop inhaled therapies for the treatment of bacterial and… Read more . . .
-
Inhaler monitoring company Adherium has announced the submission of a 510(k) for a new Hailie sensor designed specifically for use with Ellipta DPIs. In September 2021, the FDA cleared another version of the next generation… Read more . . .
-
According to Optinose, the Phase 3 ReOpen1 trial of Xhance intranasal fluticasone propionate (OPN-375) in patients with chronic sinusitus met both of its primary endpoints, demonstrating statistically significant reduction in symptoms and in sinus inflammation… Read more . . .
-
Tonix Pharmaceuticals has provided updates on two formulations of its intranasal potentiated oxytocin. The company acquired the license for one of the formulations, TNX-1900 for the treatment of migraine, from Trigemina in June 2020. According… Read more . . .
-
Device maker HCmed Innovations has partnered with Formosa Laboratories and Formosa Pharmaceuticals to offer contract development and manufacturing services for inhaled drugs, HCmed announced. Formosa Laboratories already offers CDMO services for pharmaceutical products; the new… Read more . . .
-
In December 2021, inhaled drug developer Aerami Therapeutics announced that it would go public by merging with FoxWayne Enterprises Acquisition Corp, a special purpose acquisition company (SPAC). The two companies have now announced that the deal… Read more . . .
-
According to Medical Developments International (MVP), the FDA has lifted a clinical hold on MVP’s Penthrox methoxyflurane inhaler and, as a result, MVP is now preparing a Phase 3 trial of Penthrox for trauma pain… Read more . . .
-
Sorrento Therapeutics announced that the FDA has given the company the okay to move ahead with a Phase 1 trial of its Covishield (STI-9199) intranasal antibody cocktail in healthy volunteers. According to Sorrento, in vitro… Read more . . .
-
BlueWillow Biologics and Medigen Vaccine Biologics Corporation (MVC) have announced that a preclinical study of their BW-1019 intranasal COVID-19 booster demonstrated that giving the nasal vaccine after intramuscular vaccination induced neutralizing antibodies and protected against disease in… Read more . . .
-
Non-profit pharma company Harm Reduction Therapeutics (HRT) said that a Phase 1 clinical trial of its HRT001 naloxone nasal spray in healthy volunteers met its primary endpoint, demonstrating the bioequivalence of a 3.0 mg dose… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 21-October 22: MVIC Symposium, Lund, Sweden
November 10-November 11: Rescon Europe 2026, Porto, Portugal
December 9-December 11: DDL 2026, Edinburgh, Scotland